Premium
Current Concepts in the Treatment of Multiple System Atrophy
Author(s) -
PerezLloret Santiago,
Flabeau Olivier,
Fernagut PierreOlivier,
PavyLe Traon Anne,
Rey María Verónica,
FoubertSamier Alexandra,
Tison Francois,
Rascol Olivier,
Meissner Wassilios G.
Publication year - 2015
Publication title -
movement disorders clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 18
ISSN - 2330-1619
DOI - 10.1002/mdc3.12145
Subject(s) - parkinsonism , midodrine , pure autonomic failure , medicine , cerebellar ataxia , clinical trial , intensive care medicine , neuroprotection , atrophy , olivopontocerebellar atrophy , physical medicine and rehabilitation , ataxia , neuroscience , disease , psychiatry , psychology , degenerative disease , orthostatic vital signs , blood pressure
MSA is a progressive neurodegenerative disorder characterized by autonomic failure and a variable combination of poor levodopa‐responsive parkinsonism and cerebellar ataxia ( CA ). Current therapeutic management is based on symptomatic treatment. Almost one third of MSA patients may benefit from l ‐dopa for the symptomatic treatment of parkinsonism, whereas physiotherapy remains the best therapeutic option for CA . Only midodrine and droxidopa were found to be efficient for neurogenic hypotension in double‐blind, controlled studies, whereas other symptoms of autonomic failure may be managed with off‐label treatments. To date, no curative treatment is available for MSA . Recent results of neuroprotective and ‐restorative trials have provided some hope for future advances. Considerations for future clinical trials are also discussed in this review.